NCT03422536 2024-09-04Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell CarcinomaUniversity of ArizonaPhase 2 Completed78 enrolled 16 charts
NCT01256385 2017-03-27MAESTRO HNNational Cancer Institute (NCI)Phase 2 Completed86 enrolled 11 charts